Cramer on how J&J's stock has performed in relation to vaccine news

A key Food and Drug Administration advisory panel will review and vote on Johnson & Johnson’s single-shot Covid-19 vaccine on Friday, potentially paving the way for an emergency use authorization in the coming days. CNBC's Jim Cramer and David Faber discuss.
Fri, Feb 26 20219:54 AM EST